Department of Gastroenterology and Hepatology, VU University Medical Center, 1007 MB Amsterdam, The Netherlands.
Aliment Pharmacol Ther. 2010 Feb 1;31(3):432-9. doi: 10.1111/j.1365-2036.2009.04184.x. Epub 2009 Oct 29.
Guaiac-based faecal occult blood tests (g-FOBTs) are most commonly used in colorectal cancer (CRC) screening programmes. Faecal immunochemical tests (FITs) are thought to be superior.
To compare performance of a g-FOBT and a quantitative FIT for detection of CRCs and advanced adenomas in a colonoscopy-controlled population.
We assessed sensitivity and specificity of both FIT (OC-sensor) and g-FOBT (Hemoccult-II) prior to patients' scheduled colonoscopies.
Of the 62 invasive cancers detected in 1821 individuals, g-FOBT was positive in 46 and FIT in 54 (74.2% vs. 87.1%, P = 0.02). Among 194 patients with advanced adenomas, g-FOBT was positive in 35 and FIT in 69 (18.0% vs. 35.6%, P < 0.001). Sensitivity for screen relevant tumours (197 advanced adenomas and 28 stage I or II cancers) was 23.0% for g-FOBT and 40.5% for FIT (P < 0.001). Specificity of g-FOBT compared to FIT for the detection of cancer was 95.7% vs. 91.0%, P < 0.001) and for advanced adenomas (97.4% vs. 94.2%, P < 0.001).
Faecal immunochemical test is more sensitive for CRC and advanced adenomas. Sensitivity of FIT for screen relevant tumours, early-stage cancers and advanced adenomas, is significantly higher. Specificity of g-FOBT is higher compared with FIT.
基于愈创木脂的粪便潜血试验(g-FOBT)最常用于结直肠癌(CRC)筛查计划。粪便免疫化学试验(FIT)被认为更优越。
比较 g-FOBT 和定量 FIT 在结肠镜对照人群中对 CRC 和高级腺瘤的检测性能。
我们在患者进行预定结肠镜检查之前评估了 FIT(OC-sensor)和 g-FOBT(Hemoccult-II)的敏感性和特异性。
在 1821 名个体中检测到的 62 例侵袭性癌症中,g-FOBT 阳性 46 例,FIT 阳性 54 例(74.2% vs. 87.1%,P=0.02)。在 194 例高级腺瘤患者中,g-FOBT 阳性 35 例,FIT 阳性 69 例(18.0% vs. 35.6%,P<0.001)。g-FOBT 对筛查相关肿瘤(197 例高级腺瘤和 28 例 I 期或 II 期癌症)的敏感性为 23.0%,而 FIT 的敏感性为 40.5%(P<0.001)。与 FIT 相比,g-FOBT 对癌症的检测特异性为 95.7% vs. 91.0%(P<0.001),对高级腺瘤的特异性为 97.4% vs. 94.2%(P<0.001)。
粪便免疫化学试验对 CRC 和高级腺瘤更敏感。FIT 对筛查相关肿瘤、早期癌症和高级腺瘤的敏感性显著更高。与 FIT 相比,g-FOBT 的特异性更高。